FR11C0036I2 - Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre - Google Patents

Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Info

Publication number: FR11C0036I2
Authority: FR; France
Prior art keywords: pharmaceutical compositions; compositions containing; receptor agonist; sugar alcohol; solid pharmaceutical
Prior art date: 2003-04-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR11C0036C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Mitsubishi Tanabe Pharma Corp

Original Assignee

Novartis AG

Tanabe Seiyaku Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-08

Filing date

2011-09-08

Publication date

2023-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-08 Application filed by Novartis AG, Tanabe Seiyaku Co Ltd filed Critical Novartis AG

2011-10-14 Publication of FR11C0036I1 publication Critical patent/FR11C0036I1/fr

2023-12-29 Application granted granted Critical

2023-12-29 Publication of FR11C0036I2 publication Critical patent/FR11C0036I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Hospice & Palliative Care (AREA)
Surgery (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

FR11C0036C 2003-04-08 2011-09-08 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre Active FR11C0036I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46121503P	2003-04-08	2003-04-08
PCT/EP2004/003656 WO2004089341A1 (fr)	2003-04-08	2004-04-06	Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Publications (2)

Publication Number	Publication Date
FR11C0036I1 FR11C0036I1 (fr)	2011-10-14
FR11C0036I2 true FR11C0036I2 (fr)	2023-12-29

Family

ID=32326722

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (fr)	2003-04-08	2004-04-06	Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre
FR11C0036C Active FR11C0036I2 (fr)	2003-04-08	2011-09-08	Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (fr)	2003-04-08	2004-04-06	Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre

Country Status (41)

Country	Link
US (11)	US20060275357A1 (fr)
EP (5)	EP2769713A1 (fr)
JP (3)	JP5495467B2 (fr)
KR (3)	KR20110005320A (fr)
CN (2)	CN101797241B (fr)
AR (3)	AR043987A1 (fr)
AT (3)	AT501681B1 (fr)
AU (1)	AU2004228929B2 (fr)
BE (2)	BE1015972A5 (fr)
BR (1)	BRPI0409250B8 (fr)
CA (2)	CA2521325C (fr)
CL (2)	CL2004000745A1 (fr)
CY (3)	CY1110260T1 (fr)
DE (4)	DE202004021680U1 (fr)
DK (2)	DK2316431T3 (fr)
EC (1)	ECSP056090A (fr)
ES (3)	ES2320767T3 (fr)
FR (2)	FR2854073B1 (fr)
GB (1)	GB2400318B (fr)
GR (1)	GR1005052B (fr)
HR (3)	HRP20050886B1 (fr)
HU (2)	HUE028247T2 (fr)
IL (3)	IL170888A (fr)
IS (2)	IS2682B (fr)
IT (1)	ITMI20040682A1 (fr)
LU (1)	LU91867I2 (fr)
MA (1)	MA27729A1 (fr)
MX (1)	MXPA05010860A (fr)
MY (1)	MY141249A (fr)
NO (4)	NO329332B1 (fr)
NZ (3)	NZ592339A (fr)
PE (5)	PE20150676A1 (fr)
PL (2)	PL1613288T3 (fr)
PT (1)	PT1613288E (fr)
RU (5)	RU2358716C2 (fr)
SG (1)	SG175449A1 (fr)
SI (2)	SI1613288T1 (fr)
TN (1)	TNSN05256A1 (fr)
TW (1)	TWI332847B (fr)
WO (1)	WO2004089341A1 (fr)
ZA (1)	ZA200507394B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5214966B2 (ja) *	2004-07-30	2013-06-19	ノバルティスアーゲー	２−アミノ−１，３−プロパンジオール化合物およびその類似体の製剤
CN1891212B (zh) *	2005-07-07	2010-10-13	马启明	一种口服制剂及其制备方法
CA2820510A1 (fr) *	2005-09-09	2007-03-15	Novartis Ag	Traitement de maladies auto-immunes
US7687456B2 (en)	2005-11-09	2010-03-30	Proteolix, Inc.	Compounds for enzyme inhibition
TWI389683B (zh)	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP2484688B1 (fr)	2006-06-19	2016-06-08	Onyx Therapeutics, Inc.	Peptide époxycétones destinées à l'inhibition de proteasome
GB0612721D0 (en)	2006-06-27	2006-08-09	Novartis Ag	Organic compounds
EP1905434A1 (fr) *	2006-09-26	2008-04-02	Novartis AG	Compositions organiques comprenant d'un agoniste de S1P recepteur et leur utilisation therapeutique
EP1923058A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P
AU2011235934A1 (en) *	2006-09-26	2011-11-03	Novartis Ag	Pharmaceutical compositions comprising an S1P modulator
EP1923055A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique lyophilisée comprenant un agoniste ou modulateur de S1P
KR20090057399A (ko) *	2006-09-26	2009-06-05	노파르티스 아게	Ｓ１ｐ 조정제를 포함하는 제약 조성물
EP1923054A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique à désintégration rapide comprenant un agoniste ou modulateur de S1P
WO2008124210A1 (fr) *	2007-02-14	2008-10-16	Emory University	Procédés et compositions destinés à traiter ou prévenir une infection en utilisant des agents de séquestration des leucocytes
JP4463875B2 (ja)	2007-03-29	2010-05-19	第一三共株式会社	医薬組成物
MX2010003732A (es)	2007-10-04	2010-08-09	Onyx Therapeutics Inc	Inhibidores de peptido cetona epoxi de proteasa cristalina y la sintesis de ceto-epoxidos de aminoacido.
AU2012216630B2 (en) *	2007-10-12	2015-01-22	Novartis Ag	Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
EP3733161A1 (fr) *	2007-10-12	2020-11-04	Novartis AG	Compositions comprenant des modulateurs de récepteur de sphingosine 1 (s1p) phosphate
JP5534645B2 (ja) *	2008-01-11	2014-07-02	日医工株式会社	無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
TW200946105A (en)	2008-02-07	2009-11-16	Kyorin Seiyaku Kk	Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
BRPI0909625B1 (pt)	2008-03-17	2021-09-08	Actelion Pharmaceuticals Ltd	Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
WO2009155475A1 (fr)	2008-06-20	2009-12-23	Novartis Ag	Compositions pédiatriques pour le traitement de la sclérose en plaques
RU2519768C2 (ru) *	2008-06-20	2014-06-20	Мерк Патент Гмбх	Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
ATE543393T1 (de) *	2008-09-04	2012-02-15	Cargill Inc	Erythritol-tablettierung
PE20120059A1 (es)	2008-10-21	2012-02-27	Onyx Therapeutics Inc	Combinaciones farmaceuticas con epoxicetonas peptidicas
PE20120012A1 (es)	2008-11-11	2012-02-02	Novartis Ag	Sales de fingolimod
AU2013100533B4 (en) *	2008-11-11	2013-12-12	Novartis Ag	Crystalline forms of fingolimod HCL
CN102209705A (zh) *	2008-11-11	2011-10-05	诺瓦提斯公司	芬戈莫德盐酸盐的结晶形式
JP5305421B2 (ja)	2008-12-17	2013-10-02	第一三共株式会社	ジアミン誘導体の製造方法
EP2383272A4 (fr)	2009-01-13	2012-07-25	Daiichi Sankyo Co Ltd	Inhibiteur d'un facteur actif de la coagulation sanguine
ES2542236T3 (es)	2009-03-10	2015-08-03	Daiichi Sankyo Company, Limited	Procedimiento de producción de un derivado de diamina
WO2010104106A1 (fr)	2009-03-13	2010-09-16	第一三共株式会社	Procédé de production d'un dérivé diamine optiquement actif
TWI504598B (zh)	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑
CN102481296A (zh) *	2009-06-18	2012-05-30	第一三共株式会社	溶解性改善的药用组合物
US9675566B2 (en)	2009-07-16	2017-06-13	Pathologica Llc	Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en)	2009-11-13	2014-10-07	Onyx Therapeutics, Inc.	Use of peptide epoxyketones for metastasis suppression
US9359398B2 (en)	2010-03-01	2016-06-07	Onyx Therapeutics, Inc.	Compounds for immunoproteasome inhibition
CA2793525C (fr)	2010-03-19	2014-05-06	Daiichi Sankyo Company, Limited	Procede d'amelioration de la dissolution d'un agent anticoagulant
ES2560955T3 (es)	2010-03-19	2016-02-23	Daiichi Sankyo Company, Limited	Cristal de derivado de diamina y procedimiento de producción del mismo
EA201291095A1 (ru) *	2010-04-22	2013-04-30	Рациофарм Гмбх	Способ получения пероральной лекарственной формы, содержащей финголимод
CN103080078B (zh)	2010-07-02	2015-02-11	第一三共株式会社	光学活性二胺衍生物盐的制备方法
WO2012070059A1 (fr)	2010-11-25	2012-05-31	Shilpa Medicare Limited	Polymorphes du fingolimode et leurs procédés
UA114283C2 (uk)	2011-01-07	2017-05-25	Новартіс Аг	Композиції імуносупресантів
PT2665471T (pt)	2011-01-19	2018-03-21	Pathologica Llc	Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg
JO3177B1 (ar)	2011-04-01	2018-03-08	Novartis Ag	تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EA028950B1 (ru) *	2011-08-01	2018-01-31	Тева Фармасьютикал Индастриз Лтд.	Способ получения фармацевтических композиций, содержащих финголимод
CA2844604C (fr)	2011-08-10	2017-07-18	Daiichi Sankyo Company, Limited	Composition pharmaceutique renfermant des derives d'ethanediamide
WO2013091704A1 (fr)	2011-12-22	2013-06-27	Synthon Bv	Composition pharmaceutique comprenant le fingolimod
RU2482842C1 (ru) *	2012-04-26	2013-05-27	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) *	2012-06-13	2014-02-20	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US9309283B2 (en)	2012-07-09	2016-04-12	Onyx Therapeutics, Inc.	Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) *	2012-07-11	2013-10-27	Александр Васильевич Иващенко	Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
AU2014205529B2 (en) *	2013-01-08	2018-08-09	Pathologica Llc	Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (fr) *	2013-03-11	2014-09-18	Astron Research Limited	Composition pharmaceutique stable de fingolimod
EP2990055B1 (fr) *	2013-04-26	2019-06-05	Kyoto University	Composition comprenant un agoniste du récepteur 1 de la sphingosine-1-phosphate pour empêcher la formation et/ou l'expansion d'un anévrisme cérébral ou pour réduire un tel anévrisme
WO2013190151A1 (fr) *	2013-05-13	2013-12-27	Synthon B.V.	Composition pharmaceutique contenant du fingolimod
US20160128951A1 (en) *	2013-07-29	2016-05-12	Aizant Drug Research Solutions Pvt Ltd	Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) *	2013-10-21	2014-10-10	Ооо "Валента-Интеллект"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) *	2014-08-22	2017-05-31	广东东阳光药业有限公司	一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (fr) *	2014-09-19	2016-03-24	Aizant Drug Research Pvt. Ltd	Compositions pharmaceutiques de fingolimod
US9925138B2 (en)	2015-01-20	2018-03-27	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
EP3247341A4 (fr) *	2015-01-20	2018-12-19	Handa Pharmaceuticals, Llc	Forme galénique solide stable de fingolimod
WO2016135644A1 (fr)	2015-02-26	2016-09-01	Novartis Ag	Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant
RU2577230C1 (ru) *	2015-04-09	2016-03-10	Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус"	Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) *	2015-05-28	2017-06-27	Axogen Corporation	Quantitative structural assay of a nerve graft
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (fr)	2017-03-29	2018-10-04	Deva Holding Anonim Sirketi	Formulations stables de fingolimod
GR1009654B (el)	2018-08-31	2019-11-18	Φαρματεν Α.Β.Ε.Ε.	Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) *	2018-10-10	2020-04-16	Harbins Ruhr Bioscience, Inc.	Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) *	2020-05-18	2024-06-20	東和薬品株式会社	フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
WO2022015348A1 (fr)	2020-07-16	2022-01-20	Harbins Ruhr Bioscience, Inc.	Composés sphingoïdes à utiliser dans la prophylaxie et/ou la thérapie d'une infection par un coronavirus
EP4438037A1 (fr) *	2021-01-28	2024-10-02	Priothera SAS	Méthodes de traitement avec des modulateurs du récepteur s1p

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7607683A (nl) *	1976-07-12	1978-01-16	Akzo Nv	Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) *	1977-05-05	1978-08-29	Chevron Research Company	1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en)	1983-10-25	1985-12-17	Phillips Petroleum Company	Metal working lubricant
US5112616A (en)	1988-11-30	1992-05-12	Schering Corporation	Fast dissolving buccal tablet
JP2841857B2 (ja) *	1990-11-29	1998-12-24	田辺製薬株式会社	長期間安定な経口用医薬製剤
EP0627406B1 (fr)	1992-10-21	1998-10-28	Yoshitomi Pharmaceutical Industries, Ltd.	Compose 2-amino-1,3-propanediol et immunosuppresseur
EP0778263B1 (fr)	1994-08-22	2002-01-09	Welfide Corporation	Compose benzenique et son utilisation medicale
IL121625A (en)	1995-12-28	2001-09-13	Welfide Corp	Preparation containing 2 - amino - 2 - (-2 (-4-octylphenyl) ethyl) propane - 1, 3, - dial for local topical use
JPH11209277A (ja) *	1998-01-19	1999-08-03	Yoshitomi Pharmaceut Ind Ltd	医薬組成物
US6476004B1 (en)	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
JP2002241272A (ja) *	1996-07-18	2002-08-28	Mitsubishi Pharma Corp	医薬処方組成物
GB9624038D0 (en)	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
CN1178653C (zh) *	1997-02-27	2004-12-08	三菱制药株式会社	药物组合物
RU2198162C2 (ru) *	1997-04-04	2003-02-10	Мицубиси Фарма Корпорейшн	Производное 2-аминопропан-1,3-диола, его фармацевтическое применение и промежуточные продукты для их синтеза
JPH1180026A (ja)	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja)	1998-04-01	2004-07-21	花王株式会社	スフィンゴ糖脂質の製造法
JP4627356B2 (ja) *	1999-06-30	2011-02-09	昭松森	ウイルス性心筋炎の予防または治療薬剤
WO2001003739A1 (fr) *	1999-07-12	2001-01-18	Ono Pharmaceutical Co., Ltd.	Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
BR0112484A (pt)	2000-07-13	2003-09-23	Sankyo Co	Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo
AU8533101A (en) *	2000-08-31	2002-03-13	Merck & Co Inc	Phosphate derivatives as immunoregulatory agents
US6953332B1 (en)	2000-11-28	2005-10-11	St. Jude Medical, Inc.	Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
WO2002076995A2 (fr)	2001-03-26	2002-10-03	Novartis Ag	Derives de 2-amino-propanol
US7521192B2 (en)	2001-04-18	2009-04-21	Rigel Pharmaceuticals, Inc.	EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja)	2001-04-20	2002-10-31	Sankyo Co Ltd	ベンゾチオフェン誘導体
WO2003020313A1 (fr)	2001-09-04	2003-03-13	Ono Pharmaceutical Co., Ltd.	Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
WO2003029184A1 (fr)	2001-09-27	2003-04-10	Kyorin Pharmaceutical Co., Ltd.	Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
AU2002332289B2 (en)	2001-09-27	2007-05-10	Kyorin Pharmaceutical Co., Ltd.	Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
AU2003207567B2 (en)	2002-01-18	2008-01-24	Merck Sharp & Dohme Corp.	Edg receptor agonists
JP4709488B2 (ja)	2002-01-18	2011-06-22	メルク・シャープ・エンド・ドーム・コーポレイション	Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
AU2003216054B2 (en)	2002-01-18	2007-01-04	Merck & Co., Inc.	Selective S1P1/Edg1 receptor agonists
EP1513522A2 (fr)	2002-01-18	2005-03-16	Sri International	Procedes pour traiter des pathologies associees a un recepteur d'edg
AU2005264431B2 (en) *	2004-07-16	2010-08-19	Kyorin Pharmaceutical Co., Ltd.	Method of effectively using medicine and method concerning prevention of side effect

2004
- 2004-04-06 NZ NZ592339A patent/NZ592339A/xx not_active IP Right Cessation
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en not_active IP Right Cessation
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 FR FR0450692A patent/FR2854073B1/fr not_active Expired - Lifetime
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/fr not_active Withdrawn
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/ko not_active Ceased
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/de not_active IP Right Cessation
- 2004-04-06 HR HR20050886A patent/HRP20050886B1/xx not_active IP Right Cessation
- 2004-04-06 PL PL04725895T patent/PL1613288T3/pl unknown
- 2004-04-06 HR HRP20100601AA patent/HRP20100601B1/hr not_active IP Right Cessation
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/es not_active Application Discontinuation
- 2004-04-06 SI SI200431037T patent/SI1613288T1/sl unknown
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/es not_active Application Discontinuation
- 2004-04-06 EP EP04725895A patent/EP1613288B1/fr not_active Expired - Lifetime
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/ko not_active Expired - Lifetime
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/es not_active Application Discontinuation
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/de not_active Expired - Lifetime
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/zh not_active Expired - Lifetime
- 2004-04-06 EP EP08161161A patent/EP2008650A3/fr not_active Withdrawn
- 2004-04-06 PT PT04725895T patent/PT1613288E/pt unknown
- 2004-04-06 DK DK04725895T patent/DK1613288T3/da active
- 2004-04-06 GR GR20040100121A patent/GR1005052B/el unknown
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/de not_active Expired - Lifetime
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/fr not_active Revoked
- 2004-04-06 CA CA2521325A patent/CA2521325C/fr not_active Expired - Lifetime
- 2004-04-06 EP EP10186307A patent/EP2319502A1/fr not_active Withdrawn
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/pt active IP Right Grant
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/ja not_active Expired - Lifetime
- 2004-04-06 ES ES04725895T patent/ES2320767T3/es not_active Expired - Lifetime
- 2004-04-06 ES ES200400852A patent/ES2228282B1/es not_active Expired - Fee Related
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/es active IP Right Grant
- 2004-04-06 AT AT04725895T patent/ATE414508T1/de active
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en active Active
- 2004-04-06 SI SI200432283T patent/SI2316431T1/sl unknown
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/de active Pending
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/es not_active Expired - Lifetime
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/es active IP Right Grant
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/pl unknown
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/zh not_active Expired - Lifetime
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/de not_active Ceased
- 2004-04-06 NZ NZ542622A patent/NZ542622A/xx not_active IP Right Cessation
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/fr not_active Ceased
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/ko not_active Ceased
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/it unknown
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/ru not_active IP Right Cessation
- 2004-04-06 CA CA2707750A patent/CA2707750A1/fr not_active Abandoned
- 2004-04-06 HR HR20100600A patent/HRP20100600A2/hr not_active Application Discontinuation
- 2004-04-06 AR ARP040101162A patent/AR043987A1/es not_active Application Discontinuation
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/es not_active Application Discontinuation
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/es unknown
- 2004-04-07 TW TW093109631A patent/TWI332847B/zh active
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/fr not_active IP Right Cessation
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
2005
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/es unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/fr unknown
- 2005-11-01 IS IS8114A patent/IS2682B/is unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/no active Protection Beyond IP Right Term
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/de not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/ru not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/el unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/no unknown
- 2010-02-25 IS IS8885A patent/IS8885A/is unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/ja not_active Expired - Lifetime
- 2010-10-26 AR ARP100103931A patent/AR078782A2/es not_active Application Discontinuation
- 2010-10-26 AR ARP100103930A patent/AR078781A2/es not_active Application Discontinuation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/ru active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/ru active
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/es unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/hu unknown
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
- 2011-09-08 LU LU91867C patent/LU91867I2/fr unknown
- 2011-09-08 NO NO2011016C patent/NO2011016I2/no unknown
- 2011-09-08 CY CY2011013C patent/CY2011013I1/el unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/fr active Active
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/ru not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/ja active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/no unknown
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/el unknown
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TNSN05256A1 (en)	2007-07-10
JP2011006461A (ja)	2011-01-13
EP2769713A1 (fr)	2014-08-27
EP2316431B1 (fr)	2015-09-30
IL197578A (en)	2015-10-29
HUE028247T2 (en)	2016-12-28
PE20150676A1 (es)	2015-05-17
HK1091114A1 (en)	2007-01-12
ES2228282A1 (es)	2005-04-01
US20140255497A1 (en)	2014-09-11
JP5543298B2 (ja)	2014-07-09
KR20050121712A (ko)	2005-12-27
NO334116B1 (no)	2013-12-16
CN1767819B (zh)	2010-07-28
CA2707750A1 (fr)	2004-10-21
ES2320767T3 (es)	2009-05-28
US20200237690A1 (en)	2020-07-30
US20170290787A1 (en)	2017-10-12
AU2004228929A1 (en)	2004-10-21
US20060275357A1 (en)	2006-12-07
PT1613288E (pt)	2009-02-25
ES2556947T3 (es)	2016-01-21
JP5495467B2 (ja)	2014-05-21
AR078781A2 (es)	2011-11-30
RU2358716C2 (ru)	2009-06-20
PE20050396A1 (es)	2005-07-05
LU91867I9 (fr)	2019-01-03
AT501681A1 (de)	2006-10-15
MY141249A (en)	2010-03-31
US20090203798A1 (en)	2009-08-13
NO20055231D0 (no)	2005-11-07
IS2682B (is)	2010-10-15
SI2316431T1 (sl)	2016-04-29
AT504853A2 (de)	2008-08-15
ZA200507394B (en)	2007-03-28
PE20130200A1 (es)	2013-03-09
SI1613288T1 (sl)	2009-04-30
ECSP056090A (es)	2006-03-01
CN101797241A (zh)	2010-08-11
KR20110005320A (ko)	2011-01-17
JP2013177404A (ja)	2013-09-09
HRP20100601B1 (hr)	2016-12-02
IS8885A (is)	2010-02-25
FR2854073B1 (fr)	2008-03-14
IE20040246A1 (en)	2004-12-15
IL242037A0 (en)	2015-11-30
DK1613288T3 (da)	2009-03-23
JP2004307506A (ja)	2004-11-04
ES2228282B1 (es)	2006-02-16
NO20131287L (no)	2006-01-09
FR11C0036I1 (fr)	2011-10-14
HRP20050886A2 (en)	2006-11-30
SG175449A1 (en)	2011-11-28
BE1015972A5 (fr)	2005-12-06
CL2011000450A1 (es)	2011-11-25
RU2010147000A (ru)	2012-08-10
BRPI0409250A (pt)	2006-03-28
CA2521325A1 (fr)	2004-10-21
GB0407819D0 (en)	2004-05-12
WO2004089341A1 (fr)	2004-10-21
US20080311188A1 (en)	2008-12-18
NO20055231L (no)	2006-01-09
PL2316431T3 (pl)	2016-09-30
GB2400318A (en)	2004-10-13
RU2012148593A (ru)	2014-05-20
NZ592339A (en)	2012-09-28
IL170888A (en)	2010-06-16
DK2316431T3 (en)	2016-01-11
DE202004021680U1 (de)	2010-04-22
CA2521325C (fr)	2010-09-14
NO2011016I2 (no)	2012-08-27
MXPA05010860A (es)	2006-05-25
CN1767819A (zh)	2006-05-03
US20110105620A1 (en)	2011-05-05
PL1613288T3 (pl)	2009-07-31
AU2004228929B2 (en)	2008-02-07
GR20040100121A (el)	2004-12-17
BRPI0409250B8 (pt)	2022-01-18
HK1155647A1 (en)	2012-05-25
BRPI0409250B1 (pt)	2017-07-11
EP1613288A1 (fr)	2006-01-11
GB2400318B (en)	2005-08-10
ATE414508T1 (de)	2008-12-15
CY1117071T1 (el)	2017-04-05
DE602004017847D1 (de)	2009-01-02
US20130108675A1 (en)	2013-05-02
AR078782A2 (es)	2011-11-30
PE20131352A1 (es)	2013-11-14
EP2316431A1 (fr)	2011-05-04
HK1071685A1 (en)	2005-07-29
LU91867I2 (fr)	2011-11-08
MA27729A1 (fr)	2006-01-02
DE102004016947A1 (de)	2004-10-21
CY2011013I2 (el)	2014-04-09
HRP20050886B1 (en)	2011-01-31
AR043987A1 (es)	2005-08-17
IS8114A (is)	2005-11-01
EP2008650A3 (fr)	2011-04-27
AT501681B1 (de)	2012-04-15
IL197578A0 (en)	2011-07-31
NZ542622A (en)	2009-01-31
NZ586280A (en)	2011-12-22
DE122011100047I1 (de)	2011-12-15
RU2475236C2 (ru)	2013-02-20
CL2004000745A1 (es)	2005-02-11
KR101367574B1 (ko)	2014-02-25
CN101797241B (zh)	2013-03-27
HRP20100600A2 (hr)	2011-03-31
HUS1100016I1 (hu)	2016-08-29
NO329332B1 (no)	2010-09-27
NO20100250L (no)	2006-01-09
RU2005134173A (ru)	2006-09-10
US20190175527A1 (en)	2019-06-13
EP2319502A1 (fr)	2011-05-11
NO2011016I1 (no)	2011-09-19
EP1613288B1 (fr)	2008-11-19
CY2011013I1 (el)	2014-04-09
TW200503784A (en)	2005-02-01
GR1005052B (el)	2005-11-30
RU2010146697A (ru)	2012-05-27
BE2011C030I2 (fr)	2023-03-07
NO335120B1 (no)	2014-09-22
FR2854073A1 (fr)	2004-10-29
US20220031609A1 (en)	2022-02-03
RU2009105403A (ru)	2010-08-27
KR20120101148A (ko)	2012-09-12
ITMI20040682A1 (it)	2004-07-06
RU2475237C2 (ru)	2013-02-20
US20140011885A1 (en)	2014-01-09
CY1110260T1 (el)	2014-04-09
EP2008650A2 (fr)	2008-12-31
PE20090743A1 (es)	2009-07-17
TWI332847B (en)	2010-11-11
US8324283B2 (en)	2012-12-04
HRP20100601A2 (hr)	2011-03-31

Publication	Publication Date	Title
FR11C0036I2 (fr)	2023-12-29	Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
EE200300284A (et)	2003-10-15	NMDA-retseptori agonisti farmatseutilised kompositsioonid
ZA200801575B (en)	2008-12-31	Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
ATE354362T1 (de)	2007-03-15	Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
EP1900368A4 (fr)	2009-08-12	Comprimé contenant un ingrédient actif à peine soluble
MA28527B1 (fr)	2007-04-03	Formulations orales contenant licarbazepine
EA200601015A1 (ru)	2006-10-27	Пероральные композиции дезоксипеганина и их применение
DE112004002737D2 (de)	2006-11-23	Lösungsmittel für biogene pharmazeutische Wirkstoffe
FR2884829B1 (fr)	2008-01-11	Procede d'obtention d'un extrait bacterien d'aeromonas hydrophila provenant de sangsues, et compositions pharmaceutiques les contenant
EP1626961A4 (fr)	2008-07-16	Nouveaux composes 2-oxo-heterocycliques et compositions pharmaceutiques contenant ces composes
TH72202B (th)	2019-10-25	องค์ประกอบทางเภสัชกรรมชนิดแข็งประกอบด้วย s1p รีเซพเตอร์แอกโกนิสท์และชูการ์แอลกอฮอล์
TH70717A (th)	2005-09-29	องค์ประกอบทางเภสัชกรรมชนิดแข็งประกอบด้วย s1p รีเซพเตอร์แอกโกนิสท์และชูการ์แอลกอฮอล์
TH2523C3 (th)	2006-04-24	ผลิตภัณฑ์ น้ำยาบ้วนปากเพื่อลดความอยากอาหาร
TH2523A3 (th)	2006-04-24	ผลิตภัณฑ์ น้ำยาบ้วนปากเพื่อลดความอยากอาหาร
ITMI20041849A1 (it)	2004-12-29	Formulazioni farmaceutiche per l'integrazione alimentare di soggetti anoressici
TH75914A (th)	2006-02-23	การกำหนดตำรับที่รับได้ทางรับประทานแบบของแข็งของเตโตรโดทอกซิน
DK200300002U1 (da)	2003-01-03	Farmaceutiske formuleringer indeholdende fluoxetin
HK1071685B (en)	2006-08-04	Pharmaceutical composition comprising an s1p receptor agonist